1 / 16

Daniel Maceira, Ph.D. danielmaceira@cedes danielmaceira.ar

Global Agenda on Medicines. Health Research in the South. Daniel Maceira, Ph.D. danielmaceira@cedes.org www.danielmaceira.com.ar. Objectives. Propose a Framework to Analyze Research Priorities in Health and Pharmaceuticals in Developing Nations.

herbst
Download Presentation

Daniel Maceira, Ph.D. danielmaceira@cedes danielmaceira.ar

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Global Agenda on Medicines. Health Research in the South Daniel Maceira, Ph.D. danielmaceira@cedes.org www.danielmaceira.com.ar

  2. Objectives • Propose a Framework to Analyze Research Priorities in Health and Pharmaceuticals in Developing Nations. • Provide Results about Research Projects funded by National Governments in Latin America (Argentina, Bolivia, Chile, Paraguay, Uruguay). • Identify Priority Setting Mechanisms for Health Research within a Framework of National Innovation Systems • Analyze the Presence of Coordination between Public Funding & Research Institutions in Argentina. • Discuss Specific Research Lines Developed on Pharmaceuticals under the new Argentine Macro and Institutional Context. • Suggest Principles to Include in a Collaborative Agenda.

  3. TwinTheoretical Frameworks Health Care Goods and Services Provision System Innovation System • Needs: rights and financing mechanisms. • Improve efficiency and increase allocative equity. • Generate knowledge: public goods and appropriability. • Reduce access gap and cover R&D needs. • Asymmetric Information (physician / researcher) • Incomplete Information (prob. illness / invention) • Externalities • Unequal bargaining power among parties. • The market exchange mechanisms are inefficient in both cases: It requires an intervening State (regulation, financing, provision of health goods and services).

  4. Health System National Innovation System Innovation Health System Theoretical Framework: Health Research National Innovation System Analysis of the flow of funds from the viewpoint of the supply Definition: “The network of institutions of the public and private sector whose activities and interactions initiate, import and disseminate new technologies” (Freeman, 1987). • Functions: • Provision of Research and Development (R&D), creation of new knowledge on new products, new process, new managerial techniques to improve health Status . • Creation of human capital, production and reproduction of skills to be used in R&D activities. Primary and Secondary Technology Generation (Katz, 1976) • Creation and change of the needs of the institutions to develop new fields of innovation. Innovation Health System Goal: Create Local Capabilities to Improve Public Decision Making Process in Health and Pharmaceuticals

  5. Basic Conditions Structure Strategy Performance Public Involvement & Priority Setting in Research • Income Distribution Policies • Access to Clean Water and Sanitation • Reforms on Payroll Tax Based Social Insurance Schemes Public Policy • Certification of New Drugs and Plants • Creation of Public Laboratories • Sign PAHO Revolving Fund • Licenses • Generalized Basic Package of Health Services • Price Controls • Prescription of Drugs by Generic Name • Public Purchases of Drugs for the Poor at HCCenters

  6. 18.0% 16.0% 15.7% 14.9% 14.4% 14.0% 12.0% 11.3% 10.8% 10.0% Total OOP 9.0% 8.7% OOP in Medicines 8.0% 7.6% 6.2% 6.0% 6.0% 5.7% OOP in Health Services 4.6% 4.5% 4.3% 4.0% 3.3% 2.0% 0.0% I II III IV V Income Quintile Argentina: Out of Pocket Health Expenditures, 2003 Equity Gap

  7. Methodology • Building of a database on public funding of health research ("Winning” Cases: supply and prioritization). • Classification of research topics in 27 categories (3 research methodologies and 9 objective categories).

  8. Evolution of Health Research, Public Flows. Millions of US$ PPP. 2002-2006 Source: Maceira et al (2009)

  9. DALYS, by Country. 2004 National Innovation System Health Research Priority Setting: Strategy 1: Direct Investments based on Impact (NonComm. Diseases) Strategy 2: Reduce Equity Gap. Direct Investments to Comm. Diseases Strategy 3: Improve Management and Resource Allocation within Subsystems: Direct Investments to Public Health

  10. Biomedical Objectives Social, Economic and Cultural Communicable Illnesses Non Communicable Illnesses Nutrition and Environment Violence and Accidents Health Policy, Systems & Services Technological R&D Traditional Medicine Basic Science Clinical Objectives Social, Economic and Cultural Communicable Illnesses Non Communicable Illnesses Nutrition and Environment Violence and Accidents Health Policy, Systems & Services Technological R&D Traditional Medicine Basic Science Public Health Objectives Social, Economic and Cultural Communicable Illnesses Non Communicable Illnesses Nutrition and Environment Violence and Accidents Health Policy, Systems & Services Technological R&D Traditional Medicine Basic Science Categories Priorization and Relative Participation on Allocated Resources. 2006 Objectives

  11. Publications per 10.000 inhabitants.Low Productivity Source: Maceira et al (2009)

  12. Public Funded Projects by Recipient Institution according to Methodological Category. Argentina, 2002-2006 Source: Based on information provided by ANPCyT, CONICET and Salud Investiga.

  13. Argentina New Macroeconomic & Institutional Context • No Patent Protection on Design. Import Substitution Industry. About 50% of Pharmaceutical Sales belong to Domestic Private Firms, Certified by ANMAT (Local FDA). Hidden Agenda: Avoid Intertemporal Inconsistency (Monopoly-Spread Access to Innovation) • Macroeconomic Crisis (2001): Dramatic Change in Exchange Rates affecting Import and Production Patterns in Pharmaceutical Industry • Wide Variations in Employment Rates affecting Social Insurance Coverage and Access to Medicines • New Patent Protection Law (2003) • Legislation on Prescription by Generic Name (2003) and Changes in Pharma Relative Prices (Brand Reputation & Ability to Switch) • Remediar Program (2002) : Provision to HC Centers of Medicines covering 70% of PHC Needs, Improving Access to the Poor and Reducing OOP Expenditures • Stimulus to Public Production of Pharmaceutical Products

  14. Collaborative Agenda on Pharmaceuticals in Argentina (Examples) • Social Insurance in Provinces (CEDES-Industry-MinHealth) • Efficiency of ANMAT & INPI (CIPPEC-CEDES-Industry) • Household Surveys and Health Expenditures Analysis: 2003- 2005 (CEDES-CIPPEC-Industry) • Health Systems Reforms in Middle Income Countries in Eastern Europe and Latin America (CEDES-Industry) • Remediar Program (IDB-CEDES-MinHealth) • Public Health Essential Functions Project (CEDES-MinHealth) • Superintendence of Social Health Insurance: Creation of Technological Evaluation Office • Project on Catastrophic Expenditures Funds (MinSalud-MinProvSalta-CEDES) • Estimation of Demand Functions for Therapeutic Class & Price Controls (CEDES-Industry) • Impact Estimation of Prescription by Generic Name Law (CEDES-Industry) • Courses and Conferences on Health Economics and Pharmaeconomics • Health Economics for Journalists (CEDES-Industry) • Media Articles – Trigger Public Health Agenda • Research on Key • Topics: • Impact Evaluation: • Research-to-Action • Initiatives: • Impact Regulations: • Training & Advocacy: • Collaboration in Public Policy Design • Clinical Trials & Public Hospitals (>900 in Buenos Aires Public Hospitals)

  15. Research-to-Action Project Implies: • Political Economy of Pharmaceutical Sector (Actors-Objectives-Strategies-Beliefs-Payoffs). • Public Sector: Priority Setting under Budget Constraints, Political Pressures and Urgent Needs. Institutional Capacity and Bargaining Power in Developing Countries. • Patients as Interest Group: no clear representation, discontinuous, uncomfortable as actor. Poor advocacy capacity, specially the poor. • Building Public-Research-Industry Agreements based on Public Priorities on Health Care Policy • Recognition of Each Other’s Objectives & Skills • Acknowledgment of Each Other’s Languages and Priorities • Willingness to Develop a non-Naive Common Ground for Collaboration • Recognition that there will not be “Perfect Alignment” in Goals • Need for Building Long Lasting Relations based on Technical Skills

  16. How do we get there? Requirements • Define Countries/Needs/ Supply Characteristics • Define Policy Goals s.t. a Public Priority Setting Framework • Develop Research Skills in the South within Independent Structures (Research Centers & Universities) • Develop Collaborative Training Programs favoring North-South Exchange of Experiences, Tools and Priorities • Identify Consortia between Multilateral Organizations, Developed Nations’ Agencies, Developing Governments’ Counterparts, Industry, Research Institutes • Define Spaces for Debate and Exchange of Ideas • Define an Advocacy and Communication Agenda

More Related